Page 281 - ebook HCC

PROGRAMME
GENEV
EASL HCC SUMMITHCC SUMMIT
279
278 PROGRAMME AND ABSTRACTSAND ABSTRACTS GENEVA, SWITZERLANDA, SWITZERLAND EASL 279
278
FEBRUAR
FEBRUARY 13 - 16, 2014Y 13 - 16, 2014
Poster Board Number C54
PROGENITOR CELL MARKERS IN
HEPATOCELLULAR CARCINOMA:
CLINICO-PATHOLOGICAL CORRELATIONS
AND PROGNOSTIC VALUE

Evangelia Fatourou , Despina Karandrea , John Koskinas , Marina Palaiologou , Results: K19-specific and EpCAM-specific immunoexpression were detected in tumor
4
1
3
2
Thalia Syminelaki , Menelaos Karanikolas , Evangelos Felekouras , cells of 8/74(10.81%) and 21/74 (28.37%) HCCs, respectively. K19 immunopositivity
5
6
4
Efstathios Antoniou , Emmanouil Manesis , Johanna Deladetsima , Dina Tiniakos 4 tended to correlate with micro-vascular invasion (p=0.065) but there was no correlation
7
9
8
1 Institute of Liver Studies, King’s College Hospital, London, United Kingdom, with other clinico-pathological parameters. EpCAM immunopositivity was significantly
2 Department of Pathology, Aretaieion Hospital, 2nd Department of Internal Medicine, correlated with advanced TNM stage (p=0.007). In univariate analysis, decreased
3
MedicalSchool, National & Kapodistrian University of Athens, Laboratory of Histology- recurrence-free survival (RFS) was associated with K19 immunopositivity (p<0.001),
4
Embryology, Medical School, National & Kapodistrian University of Athens, Athens, advanced TNM stage ≥ III (p=0.024) and microvascular invasion (p=0.005). Similarly,
Greece, Department of Anesthesiology, Washington University School of Medicine, decreased overall survival (OS) was significantly associated with K19 immunopositivity
5
Saint Louis, MO, United States, 1st Department of Surgery, 2nd Department of Surgery, (p=0.03) and microvascular invasion (p=0.014). In multivariate analysis, K19 positivity
7
6
9
8 2nd Department of Internal Medicine, 1st Department of Pathology, Medical School, was the only independent predictor of RFS (OR=7.534, 95%CI=2.473-22.935; p<0.001)
National & Kapodistrian University of Athens, Athens, Greece and OS (OR=3.317, 95%CI=1.195-9.208; p=0.021). EpCAM positivity did not show any
correlation with recurrence-free or overall survival.
Corresponding author’s e-mail: v_fatourou@hotmail.com
Conclusion: K19 but not EpCAM immunoexpression is an independent predictor of patient
survival in a cohort of Greek patients with HCC and could be used to subgroup HCCs
Introduction: Hepatocellular carcinoma (HCC) is a heterogeneous disease of distinct according to tumor aggressiveness. Inclusion of K19 immunopositivity, as a parameter of
clinical subgroups. Keratin 19 (K19) immunopositivity has been proposed to represent tumor aggressiveness in HCC, may increase the predictive value of currently used scoring
hepatic progenitor cell (HPC) origin of HCC and has been correlated with poorly systems.
differentiated histology and aggressive tumor behaviour. Similarly, Epithelial Cell Adhesion
Molecule (EpCAM) immunophenotype has been used to classify HCC into different
CLINICAL POSTER ABSTRACTS Aims: Aim of this study was to assess the expression of HPC markers in HCC in correlation CLINICAL POSTER ABSTRACTS
subtypes with prognostic implication and may represent a possible biomarker for HPC
origin.
with clinicopathological parameters and prognosis.
Methodology: We assessed the expression of K19 and EpCAM by immunohistochemistry
in a series of seventy-four Greek patients with HCC (mean age 65.52±10.8 years, male
72.9%) followed up for 39.6±25.3 months. HCCs were considered K19-positive or EpCAM-
positive if >5% tumor cells were immunostained.